NPHC · Nutra Pharma Corp
$0.00
At close · Sep 1
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As of the date of the filing of this report, we do not believe that our source of cash is adequate for the next 12 months of operation and there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 19, 2026
Market Cap
$715,972
Shares
7.16B
NPHC metrics
54 of 114 screener metrics currently available.
Market overview
2 metricsShare price
$0.00
Market cap
$715,972
Price action
19 metricsPrice change (1W)
+0.0%
Price change (30D)
+0.0%
Price change (3M)
-50.0%
Price change (6M)
+0.0%
Price change (YTD)
+0.0%
Price change (1Y)
+0.0%
Trailing year
Price change (5Y)
-96.7%
52-week high
$0.00
52-week low
$0.00
Change from 52-week high
-90.0%
Change from 52-week low
+0.0%
Annualized volatility
604.2%
Beta
-2.4
RSI (14D)
40.2
Price vs SMA 50
-47.9%
Price vs SMA 200
-42.0%
Avg volume (3M)
658,612
Relative volume
0.0
Average dollar volume
$128
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
7.16B
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
4.5×
reciprocal yield 22.5%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-757.1%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
78.1%
Operating margin
-1,017.8%
Trailing 12 months
Net margin
-3,370.6%
Gross profit (TTM)
$125,669
Operating profit (TTM)
−$1.64M
Net income (TTM)
−$5.42M
Trailing 12 months
Diluted EPS (TTM)
$0.00
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-59.2%
Year over year
Net income growth YoY
-1,168.5%
Revenue (TTM)
$160,815
Trailing 12 months
EPS growth YoY
—
Shares change YoY
-78.6%
Year over year · fewer shares
Revenue CAGR (3Y)
+20.9%
Revenue CAGR (5Y)
+37.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-870.3%
Debt / equity
—
Current ratio
0.0
EBITDA (TTM)
−$1.80M
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-68.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$9.73M
Latest balance sheet
Cash & equivalents
$12,181
Total assets
$622,863
Total debt
$12.57M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$1.05M
Capital expenditures (TTM)
$26,052
R&D (TTM)
$446
SG&A (TTM)
$1.47M
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Short interest
3 metricsShort interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
Flagged